Boss of Swiss pharma research association bemoans political pressure of drug prices.
The Swiss authorities also want to drive down the price of medicines
Keystone / Christian Beutler
The pharmaceutical industry is the engine of the Swiss economy. If the pharmaceutical industry is struggling, Switzerland's tax revenues will decline, says René Buholzer, CEO of Interpharma, the association of research-based pharmaceutical companies.
Generated with artificial intelligence.
This content was published on
Swiss pharma companies warn current pricing rules delay access to new medicines.
Interpharma warns Switzerland may face a US Section 301 trade probe targeting drug pricing, threatening $35.5 billion in pharma…
The pharma industry is a mainstay of the Swiss economy and a global heavyweight. But the rise of new players could shake things…
A industry-backed study estimates potential losses for the Swiss pharma industry from US policies could be in the billions.
Trump puts pressure on Swiss companies to raise pharma prices in Europe
Die Pharmaindustrie nutzt den Druck der Regierung Trump geschickt, um in Europa für teurere Arzneimittel zu lobbyieren. Statt…
